Galapagos NV Partners with UCSF for Drug Discovery
Ticker: GLPGF · Form: 6-K · Filed: Apr 8, 2024 · CIK: 1421876
| Field | Detail |
|---|---|
| Company | Galapagos NV (GLPGF) |
| Form Type | 6-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, drug-discovery, partnership
TL;DR
Galapagos teams up with UCSF for new drug discovery – pipeline boost incoming!
AI Summary
Galapagos NV announced on April 4, 2024, that it has entered into a new collaboration with the University of California, San Francisco (UCSF) to advance novel drug discovery programs. This partnership will leverage UCSF's expertise in disease biology and Galapagos' drug discovery capabilities to identify and develop new therapeutic candidates. The collaboration aims to accelerate the development of innovative treatments for various diseases.
Why It Matters
This collaboration signifies Galapagos' commitment to expanding its drug pipeline by partnering with leading research institutions, potentially leading to new treatments for unmet medical needs.
Risk Assessment
Risk Level: medium — Drug discovery is inherently risky, with high failure rates and long development timelines, making the success of this collaboration uncertain.
Key Players & Entities
- Galapagos NV (company) — Registrant
- University of California, San Francisco (UCSF) (company) — Collaboration Partner
- April 4, 2024 (date) — Announcement Date
FAQ
What is the primary goal of the collaboration between Galapagos NV and UCSF?
The primary goal is to advance novel drug discovery programs by combining UCSF's expertise in disease biology with Galapagos' drug discovery capabilities to identify and develop new therapeutic candidates.
When was the press release announcing this collaboration issued?
The press release was issued on April 4, 2024.
What type of filing is this document?
This document is a Form 6-K, a Report of Foreign Private Issuer.
Which registration statements does the information in this 6-K filing get incorporated into?
The information is incorporated by reference into Galapagos NV's Registration Statements on Form S-8, specifically File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, and 333-275886.
Where is Galapagos NV's principal executive office located?
Galapagos NV's principal executive office is located at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.
Filing Stats: 221 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-04-08 09:27:33
Filing Documents
- f6k_040424.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 23KB
- 0001171843-24-001896.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GALAPAGOS NV (Registrant) Date: April 8, 2024 /s/ Annelies Denecker Annelies Denecker Company Secretary